Clearing the Brain's Amyloid Cobwebs

  title={Clearing the Brain's Amyloid Cobwebs},
  author={Dennis J. Selkoe},
  • D. Selkoe
  • Published 25 October 2001
  • Biology
  • Neuron

Tables from this paper

Clearance of Alzheimer's Aβ Peptide The Many Roads to Perdition
Cholesterol: from heart attacks to Alzheimer's disease.
Accumulating in vitro and in vivo evidence suggests a role for cholesterol in modulating the cellular processing of Abeta with the potential to affect AD.
Plasmin Deficiency in Alzheimer’s Disease Brains: Causal or Casual?
Observations supporting the fact that plasmin paucity in the brain is not simply a secondary event in the disease but rather a primary defect in certain cases of sporadic Alzheimer’s disease are commented on.
Therapeutic strategies for Alzheimer's disease
  • M. Wolfe
  • Biology, Psychology
    Nature Reviews Drug Discovery
  • 2002
The main efforts for developing therapeutics are focused on preventing amyloid-β production, aggregation or downstream neurotoxic events and the progress of these approaches raises the hope that effective agents for the prevention and treatment of Alzheimer's disease will be available in the near future.
Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide.
A variety of approaches and mechanisms capable of modulating levels of Abeta are reviewed, which are of significant interest with regard to identifying novel disease modifying therapies for the treatment of AD.
β-Amyloid Degradation and Alzheimer's Disease
Current knowledge of Aβ-degrading enzymes, including neprilysin (NEP), endothelin-converting enzyme (ECE), insulin- degrading enzyme (IDE), angiotensin-con converting enzyme (ACE), and the plasmin/uPA/tPA system as they relate to amyloid deposition in AD are reviewed.
Deciphering the genetic basis of Alzheimer's disease.
Understanding of the genotype-to-phenotype conversions of familial AD has led to the development of pharmacological strategies to lower amyloid beta-protein levels as a way of treating or preventing all forms of the disease.
Aging, Amyloid, and Alzheimer's Disease: A Perspective in Honor of Carl Cotman
The so-called amyloid (or Aß) hypothesis of AD is well supported scientifically and predicts several specific targets for therapeutic intervention, some of which are now reaching the clinic, providing the final and most important test for this hypothetical mechanism of disease.
Mechanisms of Aβ clearance and catabolism
This review will examine the data obtained from studies performed in knockout and transgenic mice on the proteases; the cells and the physiological mechanisms that play a part in the removal of Aβ from the brain.


Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester
Results indicate that Aβ is rapidly turned over under normal conditions and support the therapeutic potential of elevating PKC activity for reduction of brain Aβ.
α-1-Antichymotrypsin Promotes β-Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer's Disease
The data demonstrate that ACT promotes amyloid deposition and provide a specific mechanism by which inflammation and the subsequent upregulation of astrocytic ACT expression in AD brain contributes to AD pathogenesis.
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
Results indicate that antibodies can cross the blood–brain barrier to act directly in the central nervous system and should be considered as a therapeutic approach for the treatment of Alzheimer disease and other neurological disorders.
Metabolic Regulation of Brain Aβ by Neprilysin
Observations suggest that even partial down-regulation of neprilysin activity, which could be caused by aging, can contribute to AD development by promoting Aβ accumulation.
Degradation of the Alzheimer's Amyloid β Peptide by Endothelin-converting Enzyme*
The identification of endothelin-converting enzyme-1 (ECE-1) as a novel Aβ-degrading enzyme is described and it is shown that recombinant soluble ECE-1 is capable of hydrolyzing synthetic Aβ40 and Aβ42 in vitro at multiple sites.
Degradation of Alzheimer's beta-amyloid protein by human cathepsin D.
It is suggested that cathepsin D may play an important role in regulating brain concentrations of beta-amyloid protein (1-40), with the same pH profile, inhibitor sensitivity and bond specificity as the activity present in human brain soluble fraction.
Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition
This NEP-catalyzed proteolysis limits the rate of Aβ42 catabolism, up-regulation of which could reduce the risk of developing Alzheimer's disease by preventing Aβ accumulation.
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.
It is shown that SAP prevents proteolysis of the amyloid fibrils of Alzheimer disease, of systemic amylidosis and of systemic monoclonal light chain amyloidsosis and may thereby contribute to their persistence in vivo.